Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ProMIS Neurosciences (PMN) will participate in the 2020 BIO CEO & Investor Conference in New York.
  • The company’s Executive Chairman, Eugene Williams, will give a presentation during the conference.
  • Mr Williams will present data which supports the company’s antibody program for neurodegenerative diseases.
  • ProMIS’s share price remains unchanged, with shares trading at $0.22 apiece.

Biotechnology company ProMIS Neurosciences (PMN) will send a representative to attend and participate in the 2020 BIO CEO & Investor Conference.

The 2-day long conference will be hosted at the Marriott Marquis Hotel in New York City.

The event will bring together investors, industry analysts, and senior executives from biotechnology and pharmaceutical companies like ProMIS.

The conference will take place on February 10th and 11th, with company presentations on both days.

The Executive Chairman of ProMIS, Eugene Williams, will give a presentation at 3:00pm (Eastern Time) on February 11th.

In his presentation, Mr Williams will present data that supports ProMIS’ antibody programs for targeting and treating neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, and ALS.

Unfortunately, webcasting will not be available for the event.

ProMIS’s share price remains unchanged, with shares trading at $0.22 apiece.

More From The Market Herald

" Revive Therapeutics (CSE:RVV) & PharmaTher (CSE:PHRM) sign MDMA research collaboration agreement

Revive Therapeutics (RVV), and PharmaTher (PHRM) have signed a research collaboration agreement.

" Defence Therapeutics (CSE:DTC) and CQDM to fund new cancer vaccine platform

Defence Therapeutics (DTC) and CQDM to fund the development of a new cancer vaccine platform.

" CENTR (CSE:CNTR) enters esports with an OpTic Gaming Media partnership

CENTR Brands (CNTR) has a new gaming influencer partnership with OpTic Gaming, a global esports and entertainment organization.

" Fobi (TSXV:FOBI) signs new PulseIR deal with Empower Clinics

Fobi AI (FOBI) announced that its wholly-owned subsidiary, PulseIR, has signed a new deal with Empower Clinics.